552 related articles for article (PubMed ID: 8910274)
21. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
Hofmann A; Blau HM
Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
[TBL] [Abstract][Full Text] [Related]
22. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo.
Rensing-Ehl A; Frei K; Flury R; Matiba B; Mariani SM; Weller M; Aebischer P; Krammer PH; Fontana A
Eur J Immunol; 1995 Aug; 25(8):2253-8. PubMed ID: 7545115
[TBL] [Abstract][Full Text] [Related]
23. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
[TBL] [Abstract][Full Text] [Related]
24. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
25. Role of fas ligand in uveal melanoma-induced liver damage.
Repp AC; Mayhew ES; Howard K; Alizadeh H; Niederkorn JY
Graefes Arch Clin Exp Ophthalmol; 2001 Oct; 239(10):752-8. PubMed ID: 11760036
[TBL] [Abstract][Full Text] [Related]
26. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
27. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
28. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
29. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
Komada Y; Sakurai M
Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
31. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
32. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis.
Batteux F; Lores P; Bucchini D; Chiocchia G
J Immunol; 2000 Feb; 164(4):1681-8. PubMed ID: 10657610
[TBL] [Abstract][Full Text] [Related]
33. Up-regulation by ammonium trichloro(dioxoethylene-0,0') tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101.
Kalechman Y; Strassmann G; Albeck M; Sredni B
J Immunol; 1998 Oct; 161(7):3536-42. PubMed ID: 9759874
[TBL] [Abstract][Full Text] [Related]
34. Fas ligand (gld)- and Fas (lpr)-deficient mice do not show alterations in the extravasation or apoptosis of inflammatory neutrophils.
Fecho K; Cohen PL
J Leukoc Biol; 1998 Sep; 64(3):373-83. PubMed ID: 9738665
[TBL] [Abstract][Full Text] [Related]
35. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S; Toomey D; Condron C; Bouchier-Hayes D
Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
[TBL] [Abstract][Full Text] [Related]
36. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
37. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. II. Deletion of effector cells by Fas-Fas ligand apoptosis.
Reich-Zeliger S; Gan J; Bachar-Lustig E; Reisner Y
J Immunol; 2004 Dec; 173(11):6660-6. PubMed ID: 15557157
[TBL] [Abstract][Full Text] [Related]
38. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway.
Favre-Felix N; Fromentin A; Hammann A; Solary E; Martin F; Bonnotte B
J Immunol; 2000 May; 164(10):5023-7. PubMed ID: 10799856
[TBL] [Abstract][Full Text] [Related]
39. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
40. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion.
Uckan D; Steele A; Cherry ; Wang BY; Chamizo W; Koutsonikolis A; Gilbert-Barness E; Good RA
Mol Hum Reprod; 1997 Aug; 3(8):655-62. PubMed ID: 9294848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]